Finkel was elected as a Member of the Association of American Physicians in 2025 in recognition of his outstanding contributions to the medical field and a commitment to fostering innovation and collaboration among physician scientists.
BA (Chemistry) - Washington and Jefferson College, Washington, Pennsylvania
Internship and Residency (Pediatrics) - Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts
Neurology Fellowship (Neurology) - Children’s, Beth Israel, Brigham and Women’s and VA Hospitals, Harvard Medical School, Boston, Massachusetts
MD - Washington University, St. Louis, Missouri
Honors & Awards
2017 Bengt Hagberg memorial lecture, Swedish Neuropediatric Society
2018 Sidney Carter Child Neurology Award, American Academy of Neurology
2019 Co-awardee of the International Prize for Translational Neuroscience of the Gertrud Reemtsma Foundation of the Max Plank Institute
Research Interests
Participation in clinical trials with investigational drugs for pediatric neurologic and metabolic diseases
Development of outcome measures, biomarkers, and clinical trial design for pediatric neurologic diseases
Understanding the trajectories of change in pediatric neuromuscular diseases: spinal muscular atrophy, Duchenne muscular dystrophy, and Charcot-Marie-Tooth inherited neuropathies.
The main goal of this study is to see if DYNE-251 is safe to use in young males with DMD. Researchers also want to find out how well DYNE-251 treats the disease and how it affects the body in other ways.
To better understand how Friedreich’s ataxia progresses and to develop tests that can be used in other clinical trials to measure changes in the disease over time.
This long-term study aims to better understand the genetic causes of Charcot-Marie-Tooth disease (CMT) and to learn how different forms of the rare hereditary disease affect people over time.
This study aims to find out if the drug apetigromab is a safe and effective treatment when used along with the standard treatment for children with spinal muscular atrophy type 2 or 3.
To investigate the safety, tolerability, and efficacy of the gene therapy OAV101 (Zolgensma®) delivered intrathecally in treatment-naïve SMA Type 2 patients between ages 2 and 18 with 2-4 copies of SMN2.
